N. Azli

发表

Current status of Taxotere® (docetaxel) as a new treatment in breast cancer

M. Glabbeke, P. Fumoleau, V. Diéras, 2004, Breast Cancer Research and Treatment.

Phase II trial of chemotherapy with 5‐fluorouracil, bleomycin, epirubicin, and cisplatin for patients with locally advanced, metastatic, or recurrent undifferentiated carcinoma of the nasopharyngeal type

J. Armand, E. Cvitkovic, N. Chouaki, 1999, Cancer.

Palliative treatment with low‐dose continuous infusion 5‐fluorouracil in recurrent and/or metastatic undifferentiated nasopharyngeal carcinoma type

J. Armand, E. Cvitkovic, A. Fandi, 1997, Head & neck.

Taxoids in combination chemotherapy for metastatic breast cancer

P. Fumoleau, V. Diéras, J. Misset, 1996, Anti-cancer drugs.

Leukemoid reaction, bone marrow invasion, fever of unknown origin, and metastatic pattern in the natural history of advanced undifferentiated carcinoma of nasopharyngeal type: a review of 255 consecutive cases.

T. Tursz, J. Armand, H. Boussen, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nasopharyngeal carcinoma: a medical oncology viewpoint. The Gustave Roussy experience.

F. Eschwège, H. Boussen, E. Cvitkovic, 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

Nasopharyngeal cancer: epidemiology, staging, and treatment.

J. Armand, E. Cvitkovic, M. Altun, 1994, Seminars in oncology.

Docetaxel in combination with doxorubicin or vinorelbine.

P. Fumoleau, V. Diéras, J. Misset, 1997, European journal of cancer.

Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5‐fluorouracil, and bleomycin

J. Armand, J. Guillaume, E. Cvitkovic, 1990, Cancer.

Chemotherapy of metastatic and/or recurrent undifferentiated nasopharyngeal carcinoma with cisplatin, bleomycin, and fluorouracil.

J. Armand, H. Boussen, E. Cvitkovic, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical implications of the serum level of CD23 in patients with undifferentiated nasopharyngeal carcinoma.

T. Tursz, J. Armand, H. Wakasugi, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Alternating chemo-radiotherapy with cisplatin and 5-fluorouracil plus bleomycin by continuous infusion for locally advanced undifferentiated carcinoma nasopharyngeal type.

J. Armand, F. Eschwège, H. Boussen, 1992, European journal of cancer.

The cycle-to-cycle variability of docetaxel pharmacokinetics (PK) assessed by population PK analysis

P. Fumoleau, M. Marty, R. Bruno, 1999 .

Cisplatin and continuous infusion vindesine and 5-fluorouracil in non-small cell lung cancer (NSCLC) (ATTIT 002). ATTIT (Association pour le Traitment des Tumeurs Intra-Thoraciques)

M. Riggi, E. Cvitkovic, I. Monnet, 1993, European journal of cancer.

Neoadjuvant chemotherapy consisting of cisplatin and continuous infusions of bleomycin and 5‐fluorouracil for advanced head and neck cancer. The need for a new stratification for stage IV (MO) disease

F. de Vathaire, E. Cvitkovic, G. Recondo, 1991, Cancer.

Docetaxel combined with vinorelbine: phase I results and new study designs.

P. Fumoleau, G. Perrocheau, N. Azli, 1997, Oncology.

Final report of a phase II study of chemotherapy with bleomycin, epirubicin, and cisplatin for locally advanced and metastatic/recurrent undifferentiated carcinoma of the nasopharyngeal type.

J. Armand, F. Eschwège, H. Boussen, 1995, The cancer journal from Scientific American.

High complete response in advanced nasopharyngeal carcinoma with bleomycin, epirubicin, and cisplatin before radiotherapy.

J. Armand, F. Eschwège, H. Boussen, 1990, Journal of the National Cancer Institute.

A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer.

G. Grasselli, L. Gianni, S. Cresta, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[Undifferentiated carcinoma of the nasopharynx: epidemiological, clinical and therapeutic aspects].

J. Armand, F. Eschwège, E. Cvitkovic, 1994, Bulletin du cancer.

Undifferentiated carcinoma of nasopharyngeal type of tonsil.

J. Klijanienko, J. Armand, F. Eschwège, 1989, Archives of otolaryngology--head & neck surgery.

Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type.

J. Armand, F. Eschwège, H. Boussen, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer.

J. Mackey, M. Smylie, K. Tonkin, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC.

P. Fumoleau, V. Diéras, P. Kerbrat, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.

M. van Glabbeke, M. Glabbeke, P. Fumoleau, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer.

V. Diéras, J. Misset, C. Jasmin, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I-II trial of recombinant interferon alpha-2b with cisplatin and 5-fluorouracil in recurrent and/or metastatic carcinoma of head and neck.

J. Armand, E. Cvitkovic, Christian Domenge, 1996, American journal of clinical oncology.

Phase II trial of recombinant interferon gamma in refractory undifferentiated carcinoma of the nasopharynx

T. Tursz, J. Armand, P. Busson, 1993, Head & neck.

Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer

S. Kaye, D. Bisset, P. Vasey, 2002, British Journal of Cancer.

Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.

M. Krzakowski, D. Campos, J. Zaluski, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer.

P. Fumoleau, V. Diéras, P. Kerbrat, 1996, British Journal of Cancer.

Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer.

M. Campone, P. Fumoleau, M. Bissery, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of sequential administration of docetaxel followed by doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer.

D. Khayat, S. Monfardini, P. Chollet, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anthracycline as second line chemotherapy (CT) for metastatic breast cancer (MBC) patients previously treated with taxotere (TXT)

P. Fumoleau, A. Riva, C. Maugard, 1997 .

A randomized phase II study of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer.

R. Paridaens, H. Hausmaninger, V. Cocquyt, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I I S tudy o f S equential A dministration o f D ocetaxel Followed b y D oxorubicin a nd C yclophosphamide a s F irst- Line C hemotherapy i n M etastatic B reast C ancer

D. Khayat, S. Monfardini, P. Chollet, 2001 .

Severe mucositis after chemotherapy with vinorelbine, 5-fluorouracil, leucovorin and cisplatin.

P. Chariot, E. Cvitkovic, I. Monnet, 1991, European journal of cancer.

938 Docetaxel (D) in combination with vinorelbine (V) as first line CT in PTS with MBC: Phase I dose finding study

P. Fumoleau, A. Riva, G. Perrocheau, 1995 .

Vinorelbine, 5-Fluorouracil, Folinic acid and Cisplatin in non-small cell lung cancer: Vindesine for Vinorelbine?

J. Armand, E. Cvitkovic, I. Monnet, 1994 .